Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804055 | 0.84 | TAAR1 (0.63) | TAAR1HRH1 | |
| SCHEMBL18539402 | 0.83 | RIPK1 (0.41) | TAAR1RIPK1IDO1KCNH2HRH1 | |
| SCHEMBL14046966 | 0.81 | TAAR1 (0.38) | PNMTTAAR1DPP4RIPK1IDO1 | |
| SCHEMBL12056288 | 0.81 | L3MBTL1 (0.50) | RIPK1MAPTKDM4ESLC6A2SLC6A4 | |
| SCHEMBL3361480 | 0.81 | RIPK1 (0.40) | TAAR1RIPK1IDO1KCNH2ALDH1A1 | |
| SCHEMBL40091 | 0.79 | GRIN2B (0.47) | PNMTTAAR1DPP4KCNH2SLC6A2 | |
| SCHEMBL29412971 | 0.79 | GRIN2B (0.47) | PNMTTAAR1DPP4KCNH2SLC6A2 | |
| SCHEMBL14667220 | 0.79 | RIPK1 (0.61) | TAAR1RIPK1IDO1KCNH2ALDH1A1 | |
| SCHEMBL8053486 | 0.79 | RIPK1 (0.39) | TAAR1RIPK1IDO1KCNH2ALDH1A1 | |
| SCHEMBL8053490 | 0.79 | RIPK1 (0.39) | TAAR1RIPK1IDO1KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| EP-3002308-B1 | SILICONE SKELETON-CONTAINING POLYMER COMPOUND AND METHOD FOR PRODUCING SAME, CHEMICALLY AMPLIFIED NEGATIVE RESIST COMPOSITION, PHOTO-CURABLE DRY FILM AND METHOD FOR PRODUCING SAME, PATTERNING PROCESS, LAYERED PRODUCT, AND SUBSTRATE | SHINETSU CHEMICAL CO (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-8394979-B2 | Process for preparing cycloplatinated platinum complexes, platinum complexes prepared by this process and the use thereof | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2013-03-12 | — | — | US | disclosed |
| EP-2220100-B1 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | RWTH AACHEN (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | RHEINISCHE-WESTFALISCHE TECHNISCHE HOCHSCHULE AACHEN (DE) | 2010-10-21 | — | — | US | disclosed |
| EP-2220100-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälisch-Technische Hochschule Aachen (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009077462-A2 | CHIRAL CYCLOPLATINIZED COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINE AND CATALYSTS | Rheinisch-Westfälische Technische Hochschule Aachen (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | PNMT 1591/4885TAAR1 1077/4885DPP4 2390/4885 |
| US-20100267977-A1 | METHOD FOR PRODUCING CYCLOPLATINIZED PLATINUM COMPLEXES, PLATINUM COMPLEXES PRODUCED BY SAID METHOD, AND THE USE THEREOF | THPO, MCL1, PPOX | PNMT 1806/4885TAAR1 4519/4885DPP4 4515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.